Jazz Pharmaceuticals Public Limited Company (JAZZ)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
121.48-1.53 (-1.24%)
At close: 4:00 PM EDT
People also watch:
ALXNMDVNREGNBMRNAKRX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open123.07
Prev Close123.01
Bid120.28 x 100
Ask123.10 x 500
Day's Range121.08 - 123.38
52wk Range108.50 - 160.00
1y Target EstN/A
Market Cap7.35B
P/E Ratio (ttm)21.36
Beta1.20
Volume659,042
Avg Vol (3m)684,207
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Jazz Pharma Closes Enrollment in OSA Drug Phase III Trial
    Zacks3 days ago

    Jazz Pharma Closes Enrollment in OSA Drug Phase III Trial

    Jazz Pharmaceuticals (JAZZ) announced the completion of patient enrollment in two phase III studies evaluating the safety and efficacy of its lead pipeline candidate JZP-110.

  • Barrons.com4 days ago

    Goldman Sachs: Pharma Stocks That Need Price Hikes to Thrive Better Find a New Strategy Fast

    Goldman Sachs analyst Jami Rubin and team argue that it's time for companies like Jazz Pharmaceuticals (JAZZ), Horizon Pharma (HZNP), and Concordia International (CXRX) to "reduce reliance on price increases." They explain: Political pressure on drug pricing has reached the point where the ability of biopharma companies to adapt to a more restrained pricing environment will differentiate winners and losers, in our view. Price increases CPI have accounted for substantial sales over past five years Our analysis suggests that pricing has played a meaningful role in industry growth, but that older products contributed heavily to the price-driven sales deltas.

  • Benzinga4 days ago

    The Drug Price Increase Debate: Separating The Winners From The Losers

    “Political pressure on drug pricing has reached the point where the ability of biopharma companies to adapt to a more restrained pricing environment will differentiate winners and losers, in our view,” ...